{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:55:50Z","timestamp":1760244950078},"reference-count":37,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2009,6,17]],"date-time":"2009-06-17T00:00:00Z","timestamp":1245196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2009,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mediastinal large B\u2010cell lymphomas (MLBCLs) are considered as a subtype of diffuse large B\u2010cell lymphoma; however, they exhibit completely different patterns of dissemination. Since they share a number of surface markers with thymic B cells, a close relationship was assumed. MLBCLs arise extranodally within the anterior mediastinum and have a low propensity to metastasize. To address the preferential positioning of MLBCL, we focused on homeostatic chemokines involved in B\u2010cell compartmental homing in secondary lymphoid organs, which are also capable of shaping lymphoid niches in ectopic sites. Here, we applied immunohistochemistry to assess chemokine receptor and ligand expression <jats:italic>in situ<\/jats:italic>. Flow cytometry was used to identify the chemokine receptor profile on an MLBCL\u2010derived cell line, Karpas1106 and on thymic B cells. Migration assays were performed to examine functionality of chemokine receptors. Electrophoretic mobility shift assay was applied to score for NF\u2010\u03baB activity. Using immunohistochemistry, we obtained an unexpectedly low\u2010expression frequency for the chemokine receptors CXCR5 and CCR7 in primary lesions. Although the mature B\u2010cell marker CCR6 was absent in most cases, the lineage aberrant marker CCR9 emerged in the majority of MLBCL cases. Given the role of NF\u2010\u03baB in the transcriptional activation of CCR7, we identified the involvement of the noncanonical activation pathway in MLBCLs. MLBCLs exhibit a diagnostic chemokine receptor profile that is instrumental in the discrimination from diffuse large B\u2010cell lymphoma not otherwise specified and classical Hodgkin lymphoma. Furthermore, we suggest that low\u2010abundance expression of CCR7 and CXCR5 may hinder lymphoma cells from nodal dissemination. \u00a9 2009 UICC<\/jats:p>","DOI":"10.1002\/ijc.24652","type":"journal-article","created":{"date-parts":[[2009,6,17]],"date-time":"2009-06-17T12:57:50Z","timestamp":1245243470000},"page":"2367-2374","source":"Crossref","is-referenced-by-count":21,"title":["Identification of a chemokine receptor profile characteristic for mediastinal large B\u2010cell lymphoma"],"prefix":"10.1002","volume":"125","author":[{"given":"Armin","family":"Rehm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Anagnostopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meike","family":"Broemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"Scheidereit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Korinna","family":"J\u00f6hrens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"H\u00fcbler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Hetzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Lipp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"D\u00f6rken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uta E.","family":"H\u00f6pken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,9,18]]},"reference":[{"key":"e_1_2_6_2_2","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.6.1855"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63815-1"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031074"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-1841"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)92622-5"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1986.tb02491.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.72.1.1"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1075"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22024"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3103"},{"key":"e_1_2_6_13_2","first-page":"3106","article-title":"CXCR4 neutralization, a novel therapeutic approach for non\u2010Hodgkin's lymphoma","volume":"62","author":"Bertolini F","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3182"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.4.1109"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI7830"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1182\/blood.V84.10.3422.3422","article-title":"B\u2010cell non\u2010Hodgkin's lymphoma cell line (Karpas1106) with complex translocation involving 18q21.3 but lacking BCL2 rearrangement and expression","volume":"84","author":"Nacheva E","year":"1994","journal-title":"Blood"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1202351"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/32.2.6198355"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1711730413"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1158\/1078-0432.28.11.1","article-title":"Small molecule inhibitors of IKB kinase are selectively toxic for subgroups of diffuse large B\u2010cell lymphoma defined by gene expression profiling","volume":"11","author":"Lam LT","year":"2005","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4901"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1576"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-075176"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-064345"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200636640"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1182-3"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1203652"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.7.2338"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1326.036"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.5.761"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.9.1241"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mn.7800196"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.5.2507"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.10.4871"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402107"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-5-488"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65424-7"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.24652","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.24652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T22:52:38Z","timestamp":1695941558000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.24652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,18]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,11,15]]}},"alternative-id":["10.1002\/ijc.24652"],"URL":"https:\/\/doi.org\/10.1002\/ijc.24652","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,18]]}}}